Table 1 Patient demographic and baseline characteristics
Characteristic | All | Conventional chemotherapy | PDX-guided chemotherapy | OR (95% CI) | P a |
|---|---|---|---|---|---|
No. | 57 | 45 | 12 | ||
Female gender, n (%) | 33 (57.89) | 26 (57.78) | 7 (58.33) | 1.02 (0.28–3.72) | 0.972 |
Age, years, n (%) | |||||
< 65 | 23 (40.35) | 18 (40) | 5 (41.67) | 1.07 (0.29–3.91) | 0.917 |
Gallstone, n (%) | |||||
Yes | 44 (77.19) | 36 (80) | 8 (66.67) | 0.5 (0.12–2.04) | 0.555 |
CA19-9, U/mL, n (%) | |||||
< 37 | 16 (28.07) | 13 (28.89) | 3 (25) | 0.82 (0.19–3.52) | 0.924 |
Tumor size, cm, n (%) | |||||
< 4 | 37 (64.91) | 31 (68.89) | 6 (50) | 0.45 (0.12–1.65) | 0.223 |
Tumor differentiation, n (%) | |||||
Well and moderate | 31 (54.39) | 23 (51.11) | 8 (66.67) | 1.91 (0.5–7.27) | 0.525 |
Nerve invasion, n (%) | |||||
Yes | 21 (36.84) | 15 (33.33) | 6 (50) | 0.5 (0.14–1.82) | 0.288 |
Lymph node metastasis, n (%) | |||||
Yes | 21 (36.84) | 14 (31.11) | 7 (58.33) | 0.4 (0.1–1.66) | 0.375 |
bTNM stage, n (%) | |||||
IIIA | 36 (63.16) | 31 (68.89) | 5 (41.67) | 0.32 (0.09–1.2) | 0.082 |
IIIB and IV | 21 (36.84) | 14 (31.11) | 7 (58.33) | ||